| Literature DB >> 31543303 |
Stanley Jin1, Satoshi Mikami2, Nick Scorah2, Young Chen2, Petro Halkowycz2, Lihong Shi2, Jason Kahana2, Patrick Vincent3, Ron de Jong2, Joy Atienza2, Robyn Fabrey2, Lilly Zhang2, Matthew Lardy4.
Abstract
Aided by Structure Based Drug Discovery (SBDD), we rapidly designed a highly novel and selective series of mTOR inhibitors. This chemotype conveys exquisite kinase selectivity, excellent in vitro and in vivo potencies and ADME safety profiles. These compounds could serve as good tools to explore the potential of TORC inhibition in various human diseases.Entities:
Keywords: Inhibitor; SBDD; mTOR
Year: 2019 PMID： 31543303 DOI： 10.1016/j.bmcl.2019.126659
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823